Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview.

Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview.
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1674-1692
Authors: Farooq MA, Aquib M, Farooq A, Haleem Khan D, Joelle Maviah MB, Sied Filli M, Kesse S, Boakye-Yiadom KO, Mavlyanova R, Parveen A, Wang B
Abstract
Cisplatin cis-(diammine)dichloridoplatinum(II) (CDDP) is the first platinum-based complex approved by the food and drug administration (FDA) of the United States (US). Cisplatin is the first line chemotherapeutic agent used alone or combined with radiations or other anti-cancer agents for a broad range of cancers such as lung, head and neck. Aroplatin™, Lipoplatin™ and SPI-077 are PEGylated liposome-based nano-formulations that are still under clinical trials. They have many limitations, for example, poor aqueous solubility, drug resistance and toxicities, which can be overcome by encapsulating the cisplatin in Nemours nanocarriers. The extensive literature from different electronic databases covers the different nano-delivery systems that are developed for cisplatin. This review critically emphasizes on the recent advancement, development, innovations and updated literature reported for different carrier systems for CDDP.
PMID: 31066300 [PubMed - in process]

Source: Artificial Cells, Nanomedicine and Biotechnology - May 9, 2019 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research